{"id":972356,"date":"2026-06-15T20:54:30","date_gmt":"2026-06-16T00:54:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/"},"modified":"2026-06-15T20:54:30","modified_gmt":"2026-06-16T00:54:30","slug":"erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/","title":{"rendered":"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSS"},"content":{"rendered":"
\n

SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (NASDAQ: ERAS<\/strong>) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca\u2019s pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015.<\/p>\n

The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026.<\/p>\n

National shareholder rights law firm Hagens Berman is continuing its investigation into legal claims that Erasca violated the federal securities laws and urges Erasca investors who suffered significant losses to contact the firm now to discuss their rights<\/strong>.<\/a><\/p>\n

\n Class Period: <\/strong>Jan. 14, 2025 \u2013 Apr. 26, 2026
Lead Plaintiff Deadline: <\/strong>Aug. 10, 2026
Visit:<\/strong>www.hbsslaw.com\/investor-fraud\/eras<\/a>
Contact the Firm Now:<\/strong>ERAS@hbsslaw.com<\/a>
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 844-916-0895<\/strong><\/p>\n

\n Erasca, Inc. (ERAS) Securities Class Action: <\/strong>\n <\/p>\n

Precision oncology company Erasca\u2019s ERAS-0015 is the company\u2019s investigational, oral, potentially \u201cbest-in-class\u201d pan-RAS molecular glue under development to treat RAS-mutant solid tumors, including pancreatic ductal adenocarcinoma.<\/p>\n

The complaint alleges that Erasca favorably compared the equivalence of its ERAS-0015 40 milligram dose cohort to RevMed\u2019s RMC-6236 400 milligram dose cohort. In addition, as recently as March 12, 2026, Erasca allegedly assured investors of its ERAS-0015 intellectual property protection, and touted that its ERAS-0015 has \u201cin-licensed one patent family from Joyo\u201d that \u201cincludes one issued US patent, one pending US non-provisional patent application, one issued foreign patent, and thirteen pending foreign patent applications.\u201d<\/p>\n

The complaint alleges that Erasca misled the market because, unknown to investors, comparisons of ERAS-0015 to RMC-6236 were improper, exposed the company to intellectual property disputes, and as a result the company\u2019s proffers about ERAS-0015 lacked a reasonable basis.<\/p>\n

The truth allegedly emerged on April 27, 2026. That day, Erasca disclosed two important matters concerning the ERAS-0015 \u201cbest-in-class\u201d narrative.<\/p>\n

First, before the market opened, Erasca disclosed that it received a letter from RevMed\u2019s legal counsel challenging the validity of Erasca\u2019s intellectual property claims. RevMed contends Erasca obtained RevMed\u2019s trade secrets through third-party misappropriation and deceptively compared the competing therapies.<\/p>\n

Second, after the market closed, the company revealed that a patient being treated with ERAS-0015 suffered an adverse event, presented to the ER a month after receiving the treatment, and then died.<\/p>\n

The market swiftly reacted to these disclosures, sending the price of Erasca shares down $9.25 (-48%) the next day and wiping out over $2.8 billion of Erasca\u2019s market capitalization.<\/p>\n

\u201cWe\u2019re investigating whether Erasca may have intentionally misled investors about ERAS-0015\u2019s safety profile and about a potential moat in its particular, highly competitive cancer treatment space,\u201d said Reed Kathrein<\/strong><\/a>, the Hagens Berman partner leading the firm\u2019s investigation.<\/p>\n

If you invested in Erasca and have substantial losses, or have knowledge that may assist the firm\u2019s investigation, submit your losses now<\/a> \u00bb<\/p>\n

If you\u2019d like more information and answers to other frequently asked questions about the Erasca case and the firm\u2019s investigation, read more<\/a> \u00bb<\/a><\/p>\n

\n Whistleblowers: <\/strong>Persons with non-public information regarding Erasca should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895<\/strong> or email ERAS@hbsslaw.com<\/a>.<\/p>\n

\n About Hagens Berman<\/a>
\n
Hagens Berman is a global plaintiffs\u2019 rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman\u2019s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at\u00a0hbsslaw.com<\/a>. Follow the firm for updates and news at\u00a0@ClassActionLaw<\/a>.<\/p>\n

\n Contact: <\/u>
\n
Reed Kathrein, 844-916-0895<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca\u2019s pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015. The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026. National shareholder rights law firm Hagens Berman is continuing its investigation into legal claims that Erasca violated the federal securities laws and urges Erasca investors who suffered significant losses to contact the firm now to discuss their rights. Class Period: Jan. 14, 2025 \u2013 Apr. … <\/p>\n

Continue reading “Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSS”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-972356","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nErasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss - HBSS - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss - HBSS - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca\u2019s pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015. The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026. National shareholder rights law firm Hagens Berman is continuing its investigation into legal claims that Erasca violated the federal securities laws and urges Erasca investors who suffered significant losses to contact the firm now to discuss their rights. Class Period: Jan. 14, 2025 \u2013 Apr. … Continue reading "Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSS"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T00:54:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSS\",\"datePublished\":\"2026-06-16T00:54:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/\"},\"wordCount\":656,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/\",\"name\":\"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss - HBSS - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI=\",\"datePublished\":\"2026-06-16T00:54:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss - HBSS - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/","og_locale":"en_US","og_type":"article","og_title":"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss - HBSS - Market Newsdesk","og_description":"SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca\u2019s pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015. The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026. National shareholder rights law firm Hagens Berman is continuing its investigation into legal claims that Erasca violated the federal securities laws and urges Erasca investors who suffered significant losses to contact the firm now to discuss their rights. Class Period: Jan. 14, 2025 \u2013 Apr. … Continue reading \"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSS\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-16T00:54:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSS","datePublished":"2026-06-16T00:54:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/"},"wordCount":656,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/","name":"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss - HBSS - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI=","datePublished":"2026-06-16T00:54:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0NzQ4NiM3NjYzMjM5IzIwMTg1MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-inc-eras-faces-securities-class-action-amid-patient-death-intellectual-property-questions-2-8-billion-market-cap-loss-hbss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss — HBSS"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=972356"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972356\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=972356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=972356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=972356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}